Impact of clinical studies on the Sentiment of drugs: A Case Study


A pharma client with a major oncology brand asked us to assess how a specific clinical study result for cHL disease affected the  HCP perceptions of their brand versus competitors worldwide.






The challenge for the client was setting up a system for global coverage of HCPs across various sources and harvesting and analyzing them in real-time:

SetuServ’s proprietary PharmaSignals platform identified ~934 global Hematology KOLs and HCPs with an active digital presence.

57% of the HCPs are from the USA, followed by 33% of HCPs from Europe. Sources such as Twitter, Semantic Scholar, PubMed,, and Oncology media sources from the US such as OncLive, TargetedOncology, and from the EU like Haematologica are covered as part of the analysis.

Analyzing the collected data of the HCPs showed that, after the interim results of the clinical study, the net sentiment of client drugs decreased significantly because of the better efficacy outcomes of the competitor’s drugs compared to the client’s drugs. In contrast, the net sentiment of competitors increased marginally.

In 2021, the net sentiment of the client’s drug improved for two reasons:

  1. Physicians mentioned Interim results of clinical study less frequently because it showed that competitor drugs had better efficacy outcomes
  2. Other clinical studies demonstrated better efficacy of the client’s drug when used in combination with other drugs, which improved the sentiment towards the client’s drug

These factors reduced the sentiment gap between the client’s drug and its competitors.

PharmaSignals will be capable of performing comparable analyses for other clinical studies or events and investigating their impact on drugs in various therapeutic areas.

To get a proof of concept on how this solution can uncover rich, actionable insights for your drug/therapeutic area, please reach out to [email protected]

Unlocking the Power of Social Listening for Pharmaceutical Companies

We recently had the opportunity to work with a BioPharma client that specializes in acquiring molecules. The client approached us with a specific challenge: they needed a mechanism for understanding physician perspectives on certain molecules, their mechanisms of action, and targeted diseases. Specifically, the client was interested in gaining insights into physicians’ views on Menin-MLL and MLL-WDR5 and which of the two is preferred for treating Heme versus Solid Tumor.

To meet this challenge, we leveraged our expertise in social listening to create a system for collecting and analyzing online data, ultimately providing the client with valuable insights into physician perspectives. In this blog post, we will share the benefits for the client from understanding physician perspectives.

We will also delve into the challenges that the client faced in setting up a social listening system and how we overcame them. By the end of this post, you’ll have a better understanding of how social listening can help pharmaceutical companies make more informed decisions and gain a competitive advantage.

The challenge for the client was setting up a social listening system for collecting online data and analyzing the data to generate insights.

Our PharmaSignals product, which is powered by custom-built APIs from a wide range of sources, proved to be an effective solution for this challenge. By collecting nearly 1,800 publications and physician tweets, our AI models extracted key entities such as Mechanism of Action, Disease, and Molecules, along with topic/sentiment analysis to capture physicians’ opinions and sentiments.

Our machine learning-based noise filtering model further identified 110 relevant articles containing both Mechanisms of Action and Disease, effectively filtering out any irrelevant articles for the analysis.

Two sample physician posts with other entities classified, showcasing how this tool can be used to extract key information:

Through our product, we were able to determine that Menin-MLL was preferred for Heme, with higher sentiment for Heme cancer, while WDR5-MLL was preferred for Solid Tumors.

Moreover, we found that within Heme, AML was the highest-mentioned disease for Menin-MLL, while within Solid Tumor, Bladder cancer was the highest-mentioned disease for WDR5-MLL.

To learn more about how we can help your pharmaceutical company make more informed decisions, please reach out to [email protected].